title: Involvement of prostaglandins in kaolin-induced writhing reaction in mice.
abstract: The relationship between the kaolin-induced writhing reaction and production of arachidonate metabolites (PGs) in mice was studied. PGs were released into the peritoneal cavity after intraperitoneal injection (i.p.) of kaolin (2.5 mg/mouse) with a peak at 5 min. About 80% of the total amount was 6-keto-PGF1 alpha. There was a significant correlation (r = 0.8237, p less than 0.001) between the number of writhes and the amount of 6-keto-PGF1 alpha. The writhing reaction induced by kaolin was significantly inhibited by simultaneous injection of soybean trypsin inhibitor (SBTI; 2.5 mg/mouse) and increased by simultaneous injection of captopril (50 micrograms/mouse). The writing reaction induced by kaolin which was inhibited by oral administration of indomethacin (1 mg/kg) was restored by exogenous i.p. injection of PGI2-Na (2-10 ng/mouse). Indomethacin, ibuprofen and alminoprofen inhibited the writhing reaction and reduced the level of peritoneal 6-keto-PGF1 alpha in parallel manner. Tiaramide, pentazocine and morphine inhibited the writhing reaction without reducing the revels of 6-keto-PGF1 alpha. These results differentiate the site of action of these analgesics. They suggest that the mechanism of the kaolin-induced writhing reaction in mice involves a synergic pain caused by simultaneously released bradykinin and PGI2. This model is a useful tool which allows differentiation of mode of action of analgesics by simultaneous determination of the writhing response and peritoneal 6-keto-PGF1 alpha.
authors.affiliation: Department of pharmacology, Kitasato University, School of Pharmaceutical Sciences, Tokyo, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Fujiyoshi
authors.forename: M
authors.initials: M
authors.lastname: Dozen
authors.forename: K
authors.initials: K
authors.lastname: Ikeda
authors.forename: S
authors.initials: S
authors.lastname: Oh-ishi
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000378:metabolism; D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D002216:Captopril / Q000494:pharmacology; D011464:Epoprostenol / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D007616:Kaolin; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D010146:Pain / Q000139:chemically induced / Q000378:metabolism / Q000503:physiopathology*; D010529:Peritoneal Cavity; D010533:Peritoneal Lavage; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011453:Prostaglandins / Q000378:metabolism / Q000502:physiology*; D014361:Trypsin Inhibitors / Q000494:pharmacology
chemical_list: D000700:Analgesics; D011453:Prostaglandins; D014361:Trypsin Inhibitors; D007616:Kaolin; D015121:6-Ketoprostaglandin F1 alpha; D002216:Captopril; D011464:Epoprostenol; D011451:Prostaglandin-Endoperoxide Synthases; D007213:Indomethacin